A detailed history of Wells Fargo & Company transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 64 shares of INDP stock, worth $64. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64
Previous 64 -0.0%
Holding current value
$64
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.0 - $2.8 $82 - $114
-41 Reduced 39.05%
64 $0
Q1 2024

May 10, 2024

BUY
$1.63 - $2.8 $1 - $2
1 Added 0.96%
105 $0
Q4 2023

Feb 09, 2024

BUY
$1.75 - $2.75 $3 - $5
2 Added 1.96%
104 $0
Q3 2023

Nov 13, 2023

BUY
$1.75 - $3.95 $1 - $3
1 Added 0.99%
102 $0
Q2 2023

Aug 15, 2023

BUY
$1.6 - $3.04 $3 - $6
2 Added 2.02%
101 $0
Q1 2023

May 12, 2023

BUY
$1.51 - $1.9 $1 - $1
1 Added 1.02%
99 $0
Q4 2022

Feb 13, 2023

BUY
$1.37 - $2.19 $1 - $2
1 Added 1.03%
98 $0
Q3 2022

Nov 14, 2022

SELL
$2.16 - $3.33 $8 - $13
-4 Reduced 3.96%
97 $0
Q2 2022

Aug 12, 2022

BUY
$1.94 - $4.02 $5 - $12
3 Added 3.06%
101 $0
Q1 2022

May 16, 2022

SELL
$3.19 - $6.17 $957 - $1,851
-300 Reduced 75.38%
98 $0
Q4 2021

Feb 14, 2022

BUY
$5.21 - $7.93 $1,740 - $2,648
334 Added 521.88%
398 $2,000
Q3 2021

Nov 15, 2021

BUY
$7.07 - $14.84 $452 - $949
64 New
64 $0

Others Institutions Holding INDP

About Indaptus Therapeutics, Inc.


  • Ticker INDP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,258,600
  • Market Cap $8.26M
  • Description
  • Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...
More about INDP
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.